Compass Therapeutics, Inc. (CMPX)Healthcare | Biotechnology | Boston, United States | NasdaqCM
0.88 USD
-0.02
(-2.108%) ⇩
(Oct. 16, 2026, 3:36 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 1:12 a.m. EDT
The investment case for Compass Therapeutics is currently defined by severe distress rather than opportunity. Fundamentally, the company is bleeding cash with negative free cash flow and negative returns on equity, while trading at a fraction of its book value. The price action confirms this deterioration, with the stock tumbling from a high of $6.88 to trade near $1.00, erasing nearly 85% of its value over the last year. While the long-term trajectory shows a recent recovery in annual returns, the underlying business remains unprofitable with no dividend support. The short-term outlook is bearish due to overwhelming options positioning. The market is pricing in a continued decline, with traders aggressively buying deep out-of-the-money puts for 2027 expiration while offering almost no call liquidity. This asymmetry suggests that even optimistic news, such as upcoming clinical data presentations, may be insufficient to reverse the trend without significant catalysts. The statistical forecasting models are unreliable, adding no clarity to the noise. Until the company demonstrates a path to profitability or a definitive regulatory approval that changes the risk profile, the balance sheet risks and lack of income make this a poor vehicle for capital preservation. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.153337 |
| AutoETS | 0.153706 |
| AutoARIMA | 0.153767 |
| AutoTheta | 0.155022 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 20% |
| H-stat | 22.68 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 1.83 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.801 |
| Market Cap | 158,081,168 |
| Forward P/E | -1.63 |
| Beta | 0.91 |
| Website | https://www.compasstherapeutics.com |
As of Oct. 10, 2026, 1:12 a.m. EDT: Speculators are overwhelmingly positioning for downside protection, evidenced by massive open interest in out-of-the-money puts expiring in late 2027 (over 41,000 contracts at the $1 strike). Conversely, call activity is negligible, with virtually no volume or open interest beyond the immediate term, indicating a lack of speculative bullish conviction despite the low implied volatility environment.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.78943664 |
| Address1 | 80 Guest Street |
| Address2 | Suite 601 |
| All Time High | 11.0 |
| All Time Low | 0.765 |
| Ask | 1.12 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 7,390,770 |
| Average Daily Volume3 Month | 4,299,754 |
| Average Volume | 4,299,754 |
| Average Volume10Days | 7,390,770 |
| Beta | 0.914 |
| Bid | 0.6278 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 0.922 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.8778 |
| Current Ratio | 11.216 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 0.9092 |
| Day Low | 0.8601 |
| Debt To Equity | 5.801 |
| Display Name | Compass Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,754,913,600 |
| Earnings Call Timestamp Start | 1,754,913,600 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | -81,013,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.108 |
| Enterprise Value | -8,761,167 |
| Eps Current Year | -0.48455 |
| Eps Forward | -0.538 |
| Eps Trailing Twelve Months | -0.39 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.78798 |
| Fifty Day Average Change | -0.91018 |
| Fifty Day Average Change Percent | -0.5090549 |
| Fifty Two Week Change Percent | -78.943665 |
| Fifty Two Week High | 6.88 |
| Fifty Two Week High Change | -6.0022 |
| Fifty Two Week High Change Percent | -0.8724128 |
| Fifty Two Week Low | 0.822 |
| Fifty Two Week Low Change | 0.05579996 |
| Fifty Two Week Low Change Percent | 0.06788316 |
| Fifty Two Week Range | 0.822 - 6.88 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,617,629,400,000 |
| Float Shares | 132,424,047 |
| Forward Eps | -0.538 |
| Forward P E | -1.6315985 |
| Free Cashflow | -31,361,124 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 39 |
| Fullday Change | -0.018900037 |
| Fullday Change Percent | -2.1077323 |
| Fullday Price | 0.8778 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.12467 |
| Held Percent Institutions | 0.88558996 |
| Implied Shares Outstanding | 180,087,915 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-11-02 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts. |
| Long Name | Compass Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 158,081,168 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_266166780 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -73,446,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 210,702,860 |
| Number Of Analyst Opinions | 11 |
| Open | 0.9 |
| Operating Cashflow | -56,110,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Phone | 617 500 8099 |
| Previous Close | 0.8967 |
| Price Eps Current Year | -1.8115777 |
| Price Hint | 4 |
| Price To Book | 0.95206076 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.153 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.018900037 |
| Regular Market Change Percent | -2.1077323 |
| Regular Market Day High | 0.9092 |
| Regular Market Day Low | 0.8601 |
| Regular Market Day Range | 0.8601 - 0.9092 |
| Regular Market Open | 0.9 |
| Regular Market Previous Close | 0.8967 |
| Regular Market Price | 0.8778 |
| Regular Market Time | 1,792,179,372 |
| Regular Market Volume | 1,159,324 |
| Return On Assets | -0.33029 |
| Return On Equity | -0.56659 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 180,087,915 |
| Shares Percent Shares Out | 0.2241 |
| Shares Short | 40,357,710 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 40,788,891 |
| Short Name | Compass Therapeutics, Inc. |
| Short Percent Of Float | 0.26790002 |
| Short Ratio | 8.74 |
| Source Interval | 15 |
| State | MA |
| Symbol | CMPX |
| Target High Price | 12.0 |
| Target Low Price | 1.0 |
| Target Mean Price | 5.45455 |
| Target Median Price | 6.0 |
| Total Cash | 179,879,008 |
| Total Cash Per Share | 0.999 |
| Total Debt | 9,633,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.39 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.440345 |
| Two Hundred Day Average Change | -2.562545 |
| Two Hundred Day Average Change Percent | -0.7448512 |
| Type Disp | Equity |
| Volume | 1,159,324 |
| Website | https://www.compasstherapeutics.com |
| Zip | 2,135 |